Abstract
Despite considerable clinical and experimental data that indomethacin can close the patent ductus arteriousus (PDA) in human newborns, reports of therapeutic failures have been published. Brash et al1 note pharmacokinetic vagaries after intravenous administration and these relate to clinical response, but most previous reports discuss orally administered indomethacin. There may be a simple pharmacologic explanation for some therapeutic failures after oral indomethacin in the newborn.
In published papers, and in many nurseries, indomethacin is usually prepared by dissolving the contents of one 25-mg capsule in 10 ml of distilled water.
- Copyright © 1982 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.